In this prospective cohort study, the health-related quality of life (HRQoL) from a societal perspective of carpal tunnel syndrome (CTS) patients was determined and compared with other diseases. In addition, the effect of carpal tunnel release (CTR) was analysed 6 weeks postoperatively with regard to mean EQ-5D index value improvement, side-effects of surgery and cost per quality adjusted life year (QALY) gained. We found a baseline mean EQ-5D index value of 0.75 (SD: 0.23), comparable with values seen in other disease like breast cancer, diabetes and asthma. Furthermore, we found that CTR improved HRQoL substantially 6 weeks postoperatively (mean + 0.12, SD: 0.22) and significantly reduced symptom reporting (mean −52%, SD: 53) with a cost per QALY gained of €396.05. In conclusion, CTS has a comparable impact on quality of life as compared with other diseases, and CTR has the potential to substantially improve patient’s HRQoL at a fairly modest cost.
AhanUArneZMBajroviFZormanP. Surgical technique to reduce scar discomfort after carpal tunnel surgery. J Hand Surg Am. 2002, 27: 821–7.
2.
AtroshiIGummessonCJohnssonROrnsteinERanstamJRosénI. [Prevalence for clinically proved carpal tunnel syndrome is 4 percent]. Lakartidningen. 2000, 97: 1668–70.
3.
BurströmKJohannessonMDiderichsenF. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001, 10: 621–35.
4.
ChapmanRHStonePWSandbergEABellCNeumannPJ. A comprehensive league table of cost-utility ratios and a sub-table of “panel-worthy” studies. Med Decis Mak. 2000, 20: 451–8.
5.
ChatterjeeAOffodileACIIAsbanA, et al.A cost-utility analysis comparing oncoplastic breast surgery to standard lumpectomy in large breasted women. Adv Breast Cancer Res. 2018, 7: 187–200.
6.
De Vet HCW, Terwee CB, Mokkink LB, Knol DL. Measurement in medicine: a practical guide. Cambridge University Press, 2011.
7.
DolanP. Modeling valuations for EuroQol health states. Med Care. 1997, 35: 1095–108.
8.
Duncan SFM, Kakinoki R. Carpal tunnel syndrome and related median neuropathies. Cham, Springer International Publishing, 2017.
GerritsenAAMde VetHCWScholtenRJPMBertelsmannFWde KromMCTFMBouterLM. Splinting vs surgery in the treatment of carpal tunnel syndrome. JAMA. 2002, 288: 1245–51.
KirkdaleRKrellJO’Hanlon BrownCTuthillMWaxmanJ. The cost of a QALY. QJM. 2010, 103: 715–20.
14.
Korthals-de BosIBCGerritsenAAMvan TulderMW, et al.Surgery is more cost-effective than splinting for carpal tunnel syndrome in the Netherlands: results of an economic evaluation alongside a randomized controlled trial. BMC Musculoskelet Disord. 2006, 7: 86.
15.
LamersLMMcDonnellJStalmeierPFMKrabbePFMBusschbachJJV. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ. 2006, 15: 1121–32.
16.
LaupacisAFeenyDDetskyASTugwellPX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992, 146: 473.
17.
LiNVan AgthovenMWillemsePHBUyl-De GrootCA. A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer. Anticancer Drugs. 2001, 12: 533–40.
18.
MartiCHenslerSHerrenDBNiedermannKMarksM. Measurement properties of the EuroQoL EQ-5D-5L to assess quality of life in patients undergoing carpal tunnel release. J Hand Surg Eur. 2016, 41: 957–62.
19.
MøllerAHErntoftSVindingGRJemecGB. A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat Outcome Meas. 2015, 6: 167–77.
20.
NeumannPJCohenJTWeinsteinMC. Updating cost-effectiveness – the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014, 371: 796–7.
21.
PomeranceJZurakowskiDFineI. The cost-effectiveness of nonsurgical versus surgical treatment for carpal tunnel syndrome. J Hand Surg Am. 2009, 34: 1193–200.
22.
SmuldersYMThijsA. Kostprijs per gewonnen levensjaar: Trends en tegenstrijdigheden. Ned Tijdschr Geneeskd. 2006, 150: 2467–70.
23.
SullivanPWGhushchyanV. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak. 2006, 26: 410–20.
24.
SullivanPWSlejkoJFSculpherMJGhushchyanV. Catalogue of EQ-5D Scores for the United Kingdom. Med Decis Mak. 2011, 31: 800–4.
25.
Szende A, Janssen B, Cabasés J. Self-reported population health: an international perspective based on EQ-5D. Dordrecht, Springer Netherlands, 2014.
26.
US Department of Health and Human Services, PHS. The International Classification of Diseases, 9th revision, Clinical Modification: ICD-9-CM. 2nd ed. 1980. Washington, DC, US Health Care Financing Administration.
27.
Verdugo RJ, Salinas RA, Castillo JL, Cea G. Surgical versus non-surgical treatment for carpal tunnel syndrome. Cochrane Database Syst Rev. 2008. 4: CD001552.
28.
WaltersSJBrazierJE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005, 14: 1523–32.
